NASDAQ:RVNC Revance Therapeutics - RVNC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $33.04 +0.35 (+1.07%) (As of 03/28/2023 10:03 AM ET) Add Compare Share Share Today's Range$32.41▼$33.1250-Day Range$28.03▼$35.2752-Week Range$11.27▼$36.61Volume39,749 shsAverage Volume1.59 million shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice Target$40.91 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Revance Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside25.2% Upside$40.91 Price TargetShort InterestBearish14.88% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment1.47Based on 4 Articles This WeekInsider TradingSelling Shares$4.42 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.78) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector159th out of 995 stocksPharmaceutical Preparations Industry64th out of 482 stocks 4.4 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.91, Revance Therapeutics has a forecasted upside of 25.2% from its current price of $32.69.Amount of Analyst CoverageRevance Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.88% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Revance Therapeutics has recently increased by 2.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 3.0 News and Social Media Coverage News SentimentRevance Therapeutics has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Revance Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for RVNC on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,421,806.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions82.68% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($2.78) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -6.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -6.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevance Therapeutics has a P/B Ratio of 217.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Revance Therapeutics (NASDAQ:RVNC) StockRevance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.Read More Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RVNC Stock News HeadlinesMarch 2, 2023 | marketbeat.comWall Street Sees 23% Upside In Revance, Maker Of Botox CompetitorRevance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify.March 23, 2023 | americanbankingnews.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 28, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 18, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Raised to "Hold" at StockNews.comMarch 14, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Revance Therapeutics (RVNC)March 7, 2023 | finance.yahoo.comRevance to Participate in Upcoming Investor ConferencesMarch 3, 2023 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Call TranscriptMarch 1, 2023 | finance.yahoo.comQ4 2022 Revance Therapeutics Inc Earnings CallMarch 28, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 1, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Revance Therapeutics (RVNC)March 1, 2023 | finance.yahoo.comRevance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent DirectorMarch 1, 2023 | finance.yahoo.comRevance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate UpdateMarch 1, 2023 | finance.yahoo.comRevance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue EstimatesFebruary 27, 2023 | finance.yahoo.comReasons for the Decline of Revance Therapeutics (RVNC) in Q4February 27, 2023 | finance.yahoo.comRevance to Participate in the 43rd Annual Cowen Healthcare ConferenceFebruary 24, 2023 | finance.yahoo.comRevance Therapeutics (NASDAQ:RVNC) shareholders have earned a 154% return over the last yearFebruary 24, 2023 | finance.yahoo.comWhy Unprofitable Stocks Make The IBD 50; Here's How 4 Earn Their PlaceFebruary 23, 2023 | finance.yahoo.comRevance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual MeetingFebruary 21, 2023 | finance.yahoo.comRevance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023February 20, 2023 | thestreet.comJim Cramer -- Revance's Drug Results Are Better Than Allergan's BotoxFebruary 2, 2023 | finance.yahoo.comWhat Makes Revance Therapeutics, Inc. (RVNC) a Strong Momentum Stock: Buy Now?January 30, 2023 | 247wallst.comJPMorgan Chase Cuts Stake in Revance TherapeuticsJanuary 24, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Revance TherapeuticsJanuary 23, 2023 | finance.yahoo.comRevance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?January 11, 2023 | marketwatch.comRevance Therapeutics Shares Rally on Antiwrinkle Treatment Daxxify's Advances >RVNCJanuary 9, 2023 | finance.yahoo.comRevance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial ResultsJanuary 6, 2023 | finance.yahoo.comRevance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical DystoniaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RVNC Company Calendar Last Earnings2/28/2023Today3/28/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees495Year FoundedN/APrice Target and Rating Average Stock Price Forecast$40.91 High Stock Price Forecast$65.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+25.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-356,420,000.00 Net Margins-268.87% Pretax Margin-268.34% Return on Equity-786.70% Return on Assets-57.14% Debt Debt-to-Equity Ratio30.11 Current Ratio4.95 Quick Ratio4.71 Sales & Book Value Annual Sales$132.57 million Price / Sales20.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book217.90Miscellaneous Outstanding Shares82,800,000Free Float78,577,000Market Cap$2.71 billion OptionableOptionable Beta0.86 Key ExecutivesMark J. FoleyChief Executive Officer & DirectorDustin S. SjutsPresidentTobin C. SchilkeChief Financial OfficerAzita NejadSenior Vice President-Technical OperationsRoman G. RubioSenior Vice President-Clinical DevelopmentKey CompetitorsMyovant SciencesNYSE:MYOVUltragenyx PharmaceuticalNASDAQ:RAREBlueprint MedicinesNASDAQ:BPMCArrowhead PharmaceuticalsNASDAQ:ARWRHUTCHMEDNASDAQ:HCMView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 3,200 shares on 3/23/2023Ownership: 0.051%Mark J FoleySold 70,390 sharesTotal: $2.22 M ($31.59/share)Dustin S SjutsSold 21,508 sharesTotal: $679,437.72 ($31.59/share)Tobin SchilkeSold 18,517 sharesTotal: $584,952.03 ($31.59/share)Dwight MoxieSold 18,496 sharesTotal: $584,288.64 ($31.59/share)View All Insider TransactionsView All Institutional Transactions RVNC Stock - Frequently Asked Questions Should I buy or sell Revance Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks. What is Revance Therapeutics' stock price forecast for 2023? 8 brokerages have issued 12 month target prices for Revance Therapeutics' stock. Their RVNC share price forecasts range from $26.00 to $65.00. On average, they predict the company's share price to reach $40.91 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts. How have RVNC shares performed in 2023? Revance Therapeutics' stock was trading at $18.46 at the start of the year. Since then, RVNC stock has increased by 77.1% and is now trading at $32.6850. View the best growth stocks for 2023 here. When is Revance Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our RVNC earnings forecast. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its quarterly earnings data on Tuesday, February, 28th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.04) by $0.78. The biopharmaceutical company earned $49.90 million during the quarter, compared to analysts' expectations of $45.10 million. Revance Therapeutics had a negative net margin of 268.87% and a negative trailing twelve-month return on equity of 786.70%. The company's quarterly revenue was up 92.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.93) earnings per share. What ETFs hold Revance Therapeutics' stock? ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), SPDR S&P Pharmaceuticals ETF (XPH), Innovator IBD 50 ETF (FFTY), iShares U.S. Pharmaceuticals ETF (IHE), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC) and Inspire Small/Mid Cap ETF (ISMD). What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO). What is Revance Therapeutics' stock symbol? Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC." Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (6.10%), Jennison Associates LLC (2.46%), Geode Capital Management LLC (1.87%), Antara Capital LP (0.00%), Two Sigma Investments LP (1.64%) and Bamco Inc. NY (1.53%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Revance Therapeutics' stock price today? One share of RVNC stock can currently be purchased for approximately $32.69. How much money does Revance Therapeutics make? Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $2.71 billion and generates $132.57 million in revenue each year. The biopharmaceutical company earns $-356,420,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. How many employees does Revance Therapeutics have? The company employs 495 workers across the globe. How can I contact Revance Therapeutics? Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401. This page (NASDAQ:RVNC) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.